Brittany Meiling

Brittany is the Biotech Reporter for the San Diego Business Journal. She covers drug development, genomics, medtech, digital health and early-stage funding for life science. She particularly likes taking on topics in pharma. Previously, she worked at Springfield Business Journal. She graduated from Missouri State University with a degree in journalism with an emphasis in business reporting.

Posts by Brittany Meiling

Startups, Diagnostics

ID Genomics Founder: We must personalize how we treat bacteria

ID Genomics Founder Evgeni Sokurenko said the company intends to have FDA approval for the test by 2018. It will cost about $10.

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

Partnership Post

When Investment Rhymes with Canada

Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.

By Julien Rosan and Tina Kotrych - Global Affairs Canada